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Introduction
The use of high dose therapy (HDT) and autologous
stem cell transplantation (ASCT) for patients with lym-
phoma has increased rapidly during the last decade. It is
now widely accepted as 'standard' salvage therapy in cer-
tain patients with relapsed Hodgkin's disease and non-
-Hodgkin's lymphoma (NHL), where small randomized
trials have demonstrated the superiority of HDT over
'conventional' dose salvage therapy. In addition, it is now
being assessed as post-remission therapy in some patients
with NHL (and to a lesser extent with Hodgkin's dise-
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High dose therapy and autologous stem cell transplantation (ASCT) has been extensively investigated in the treatment of ma-
lignant lymphoma, both as salvage treatment, and as a component of first line therapy. Few randomized trials have been con-
ducted, and most evidence is from the retrospective registry-based, or single institution studies. The use of ASCT as salvage the-
rapy for patients with all subtypes of aggressive NHL, or with Hodgkin's disease, who have relapsed after initial chemothera-
py, is now a standard of care. In patients with diffuse large B-cell NHL, the survival benefit is restricted to these whose disease
is still responsive to 'conventional dose' chemotherapy. The use of ASCT for patients with primary refractory disease is contro-
versial, although retrospective evidence supports its use in patients with Hodgkin's disease, but not those with aggressive
NHL. The use of ASCT as a component of first line therapy remains uncertain. For patients with diffuse large B-cell NHL,
trials in patients not selected for risk factors have failed to show a survival advantage for ASCT. Trials in patients with 'poor
risk' disease as defined by the International Prognostic Index are in progress, and at present, ASCT in this context cannot be
recommended except in clinical trials. First remission ASCT for patients with lymphoblastic lymphoma has been compared
with conventional dose consolidation therapy. Preliminary results from a single randomized trial show a progression free su-
rvival advantage for ASCT in this disease. Although retrospective data have demonstrated encouraging results for this appro-
ach in patients with Burkitt's and Burkitt-like NHL, the excellent results of recent dose intensive, non-transplant regimens for
these diseases suggest, that first remission ASCT should not be considered a routine for these patients. The potential long term
toxicity of ASCT in patients with Hodgkin's disease, and the favorable outcome for this patient group precludes its widespre-
ad use as part of the first line therapy, although one randomized trial addressing this issue is in progress.
Zastosowanie chemioterapii w wysokich dawkach z póêniejszym  przeszczepieniem
autologicznych komórek macierzystych szpiku w leczeniu chorych na ch∏oniaki z∏oÊliwe: obecny stan wiedzy
Chemioterapia wysokodawkowana i przeszczepy autologicznych komórek macierzystych szpiku (ASCT) sà przedmiotem in-
tensywnych badaƒ klinicznych w leczeniu ch∏oniaków z∏oÊliwych (ch∏oniaki nieziarnicze i ziarnica z∏oÊliwa) zarówno jako pro-
gram terapii ratunkowej, jak i cz´Êç terapii pierwszej linii.
Dost´pne dane piÊmiennicze oparte sà albo o wyniki mi´dzyoÊrodkowych kontrolowanych doÊwiadczeƒ klinicznych z losowym
doborem chorych, albo o dane retrospektywne, albo o wyniki prezentowane przez pojedyncze oÊrodki badawcze.
W artykule omówione zosta∏y szczegó∏owo wskazania do zastosowania ww. procedur wysokospecjalistycznych w leczeniu ch∏o-
niaków i ziarnicy z∏oÊliwej, ze szczególnym podkreÊleniem w jakich przypadkach ASCT mo˝e byç uznane ju˝ dzisiaj za
standard leczenia.
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niaki z∏oÊliwe
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ase) after an initial remission induction has been achieved
with standard dose therapy.
Improvements in supportive care for patients un-
dergoing HDT and ASCT, particularly the use of peri-
pheral blood progenitor cells (PBPCs) in place of bone
marrow, have markedly reduced the toxicity of HDT. This
has allowed studies of ASCT in first remission to be per-
formed without an excessive risk of treatment-related
mortality, and has also increased the upper age limit of
patients in whom HDT can be used, thus expanding the
potential patient population. These trends, coupled with
the well-documented increase in the incidence of NHL,
suggest that the potential patient population in whom
HDT could be used will increase substantially. It is there-
fore essential that the impact of HDT and ASCT on survi-
val in these diseases remains a priority for prospective
randomized trials.
Although the use of HDT in indolent lymphoma
(particularly follicular lymphoma) has been under investi-
gation for several years, no data are currently available
from randomized trials in these diseases. More recently,
HDT has been used as part of first line and salvage thera-
py in mantle cell lymphoma, but at present, data are only
available from retrospective, or phase II studies. High
dose strategies should still be regarded as experimental in
these diseases. Most studies of HDT and ASCT in lym-
phoma have been performed in patients with Hodg-
kin's disease or aggressive NHL.
Diffuse large B-cell lymphoma (DLBCL)
S a l v a g e  t h e r a p y
The use of HDT and ASCT as salvage therapy for pa-
tients with chemosensitive relapse of DLBCL and other
related aggressive subtypes of NHL is now one of the
most established uses of this therapy, supported by the re-
sults of the PARMA randomized trial [1]. In this study,
patients with relapsed, aggressive NHL initially received
2 cycles of DHAP (dexamethasone, high dose cytosine
arabinoside, cisplatin). Responding patients were then
randomized either to continue with 4 further cycles of
DHAP, or to receive high dose therapy using BEAC
(carmustine, etoposide, cytosine arabinoside, cyclopho-
sphamide. Involved field radiotherapy was given to sites of
initial bulky disease in both arms of the trial. Of the initial
215 patients entered onto the study, 106 were not rando-
mized, either because of failure to respond to the first 2
cycles of DHAP (90) or for various other reasons inclu-
ding patient refusal, or high reported toxicity from DHAP.
At the time of the initial report (median follow up 63
months), the 5 year actuarial event free survival was 46%
in the transplant arm, and 12% in the DHAP arm (p =
0.001). the corresponding figures for 5 year overall su-
rvival were 53% and 32% (p = 0.038). The results of the
study were updated in 1998, at which time the median
follow up was 100 months[2]. The 8 year event free survi-
val rates were 36% in the transplant arm and 11% in the
DHAP arm (p = <0.002). Corresponding figures for ove-
rall survival were 47% and 27% (p = 0.042).
These results confirm the superiority of HDT over
conventional dose salvage therapy in patients whose dise-
ase is still responsive to conventional dose therapy given
prior to high dose therapy. HDT and ASCT is standard
therapy in this patient group.
The outlook for patients with chemoresistant relap-
se is very poor, and data from retrospective studies show
that long term disease free survival after HDT and ASCT
is rare in this group.
F i r s t  l i n e  t h e r a p y
Primary refractory disease
Most large retrospective series of HDT and ASCT in ag-
gressive NHL, either registry-based or single center, have
included small numbers of patients with primary refracto-
ry disease. Very few patients undergoing ASCT in this
situation appear to have achieved long term disease free
survival. A recent study from Cologne has confirmed this,
demonstrating that only a small minority of patients with
primary refractory NHL are suitable for HDT, because of
age, performance status, rate of disease progression, etc,
and that none of the patients receiving HDT and ASCT
survived for more that 1 year [3]. A further analysis of
outcome for this group is currently being undertaken by
the Autologous Blood and Marrow Transplant Registry of
North America (ABMTR).
Patients who are 'slow responders' to initial chemothe-
rapy
Previous analyses of patients with aggressive NHL tre-
ated with CHOP (cyclophosphamide, doxorubicin, vin-
cristine, prednisone) or related regimens have shown that
patients who have achieved complete remission (CR)
after 3 cycles of therapy have a higher probability of long
term disease free survival than those who enter remis-
sion more slowly, or who fail to achieve complete remis-
sion after completion of all therapy.
The use of HDT and ASCT in this situation has be-
en assessed in 2 randomized trials. In a study conducted in
the Netherlands, 286 eligible patients with aggressive
NHL were initially treated with CHOP chemotherapy,
133 of whom were in partial remission after 3 cycles [4].
Twenty seven of these were ineligible for randomization
since they had persistent disease in the bone marrow. Of
the remaining 106 patients who were eligible for randomi-
zation, only 65 were randomized, either to high HDT
(high dose cyclophosphamide and total body irradiation
[TBI]), or to continue with 5 further cycles of CHOP.
There was no significant difference in 4 year overall (ha-
zard ratio for ASCT vs CHOP = 2.2; 95% CI = 0.82 –
5.9; p = 0.12) or event free survival (hazard ratio 1.3;
95% CI = 0.66 – 2.61; p = 0.43). Martelli et al reported
similar findings in 49 patients who were slow responders
to MACOP-B or F-MACHOP chemotherapy, and who
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were randomized either to receive non-cross resistant,
conventional dose therapy with DHAP, or HDT and
ASCT [5]. No difference in overall or event free survival
was observed according to randomized arm.
HDT/ASCT as a component of first line therapy
Combination chemotherapy using CHOP is currently re-
cognized internationally as standard therapy for patients
with advanced aggressive NHL. Numerous single insti-
tution phase II studies conducted in the 1980s showed
apparently superior response and survival rates for more
dose-intensive chemotherapy regimens. However, the lar-
ge randomized study conducted by the Southwest Onco-
logy Group (SWOG) in the USA showed no difference in
response rates, disease free or overall survival when
CHOP was compared with m-BACOD (methotrexate,
bleomycin, doxorubicin, cyclophosphamide, vincristine,
dexamethasone), MACOP-B (methotrexate, doxorubi-
cin, cyclophosphamide, vincristine, prednisone, bleomy-
cin), or ProMACE, CytaBOM (procarbazine, methotrexa-
te, doxorubicin, cyclophosphamide, etoposide, cytosine
arabinoside, bleomycin, vincristine, methotrexate) [6].
A British National Lymphoma Investigation (BNLI) ran-
domized trial comparing CHOP with PACEBOM also
showed no difference in response rates, disease free or
overall survival [7].
In view of the effectiveness of high dose therapy and
ASCT for patients with relapsed disease, several randomi-
zed studies have been conducted in which patients achie-
ving an objective response to conventional dose induc-
tion therapy have been randomized either to continue
with conventional dose therapy, or to receive high dose
therapy and ASCT. Several such studies were initiated
prior to the description of the International Prognostic In-
dex (IPI). Such studies include the GELA LNH-87 trial
[8], and the EORTC 20901 trial, both of which assessed
the use of 1st remission high dose therapy with no risk
stratification. No difference in overall or disease free su-
rvival was observed in these studies.
The development of the International Prognostic
Index has provided a reproducible clinical model in which
clinical features at presentation can be used to stratify
patients into prognostic groups [9]. The prognostic model
includes 5 adverse factors – advanced age (>60 years), ad-
vanced stage, elevated serum lactate dehydrogenase
(LDH), > 1 extranodal site of disease and poor perfor-
mance status. In addition, an age-adjusted prognostic
model was developed for patients aged <60 years, inclu-
ding advanced stage, LDH, and performance status only.
Following the description of the IPI, the results of
the LNH-87 trial were re-analyzed according to IPI risk
groups [10]. Patients in the high/intermediate (H/I) and
high (H) risk groups had superior DFS and OS rates
when treated with high dose consolidation and ASCT
compared with those patients who received conventio-
nal dose sequential consolidation therapy (5 year actuarial
DFS = 57% for high dose versus 36% for conventional
dose (p=0.01); 5 year actuarial OS = 65% for high dose
versus 52% for conventional dose [p=0.06]). No diffe-
rence in OS or DFS was observed for patients in the low
(L) or low/intermediate (L/I) risk groups. A recent upda-
te of these data has confirmed these trends (8 year actu-
arial DFS = 55% for high dose versus 39% for conventio-
nal dose (p = 0.02); 8 year actuarial OS = 64% for high
dose versus 49% for conventional dose [p = 0.04]) [11].
These data must be interpreted cautiously, since they re-
present a retrospective, subset analysis from a non-strati-
fied prospective clinical trial, but they suggest a possible
role for high dose consolidation in patients with poor risk
disease.
Several randomized trials of early intensification,
using high dose therapy and ASCT have now been re-
ported for poor risk patients, and several others are in
progress.
GELA have recently reported results for the LNH-
-93 trial [12]. This was a randomized comparison of co-
nventional chemotherapy using ACVB (doxorubicin, cyc-
lophosphamide, vinblastine, bleomycin) followed by co-
nventional dose sequential consolidation therapy,
compared with and experimental intensified induction
regimen CEOP (cyclophosphamide, epirubicin, vincristi-
ne, prednisone) plus ECVBP (epirubicin, cyclophospha-
mide, vindesine, bleomycin, prednisone)) followed by
high dose therapy and ASCT. Patients aged <60 years,
with 2 or 3 adverse risk factors according to the age-adju-
sted IPI were eligible. Accrual to the study was closed
after an interim analysis. At the time of the most recent
report, with a median follow up of 30 months, the 3 year
EFS was 54% for the conventional arm versus 41% for the
high dose arm (p = 0.01), and the 3 year OS was 63% for
the conventional dose arm versus 47% for the high dose
arm (p = 0.003).
The German High Grade Lymphoma Study Group
are conducting a study comparing 3 cycles of chemothera-
py using CHEOP (cyclophosphamide, doxorubicin, etopo-
side, vincristine, prednisone) followed by high dose thera-
py and ASCT, with 5 cycles of CHEOP alone, for patients
aged <60, with an elevated LDH. No difference in DFS
or OS was reported at the first interim analysis of this
trial, or in the most recent update, and analysis using IPI
risk groups shows no differences in outcome in any risk
groups [13].
The Italian NHL Study Group have recently comple-
ted a trial comparing VACOP-B (etoposide, doxorubi-
cin, cyclophosphamide, vincristine, prednisone) alone
with VACOP-B followed by high dose therapy and ASCT
for 'poor risk' patients (defined as bulky stage II, stages III
and IV) [14]. When all patients were analyzed, no diffe-
rence in DFS or OS was observed. Subset analysis showed
a significant improvement in DFS for IPI H/I and H risk
groups receiving high dose therapy (6 year actuarial DFS
= 87% for high dose compared with 48% for conventio-
nal dose therapy, p = 0.008). However, no difference in
PFS or OS was observed.
Recent studies of 'early' intensification have been
notable for the relatively high rate of early progressive di-
sease in patients receiving induction therapy prior to high
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dose consolidation. In the GELA LNH-93-3 trial, 29% of
patients had progressed before reaching the high dose
phase of the trial [15]. Similarly, in the German High
Grade Lymphoma Study Group trial, 33% of patients fa-
iled to reach the high dose phase, mainly due to disease
progression [16]. In The current LY02 trial, the corre-
sponding figure is approximately 30%.
In contrast to most of the studies mentioned abo-
ve, the GOELAMS group have recently reported initial
results of a randomized trial comparing 8 cycles of CHOP
chemotherapy with 2 cycles of CEEP (cyclophosphamide,
epirubicin, vindesine, prednisone) plus ASCT in patients
with non-high risk aggressive NHL according to the age-
-adjusted IPI [15]. They report a superior 4 year event
free and failure free survival in the high dose arm, altho-
ugh there is no overall survival benefit, except in the sub-
group with high-intermediate risk disease (3 year OS =
78% vs 43%, p = 0.01).
An alternative approach to dose intensive therapy
in NHL has been the development of high dose sequential
therapy. This uses non-cross-resistant drugs, given at near
maximum tolerated doses, in a sequential fashion, suppor-
ted by the use of haemopoietic growth factors, and autolo-
gous peripheral blood progenitor cells (Figure 1). This
might therefore reduce the potential for early progressive
disease which characterizes the protocols described above.
The Milan group have recently reported the results of
a randomized trial comparing this high dose sequential
(HDS) regimen with MACOP-B chemotherapy for pa-
tients with poor risk disease (bulky stage I or II, stage III
or IV) [18]. 74% of patients in the MACOP-B arm were
IPI H or H/I risk, compared with 94% in the HDS arm
[16]. A total of 98 patients were randomized. With a me-
dian follow up of 55 months at the time of the report, the
results were as summarized in Table I.
HDS therapy was well tolerated. Three toxic deaths
occurred in the first 30 patients, who received a TBI-ba-
sed high dose regimen. This was subsequently modified to
high dose mitoxantrone and melphalan, and no further to-
xic deaths have occurred. Overall, much more extrame-
dullary toxicity was observed in patients receiving HDS
compared with those receiving MACOP-B.
The applicability of this HDS regimen in a multi-
-center context has been assessed in a pilot study by the
Eastern Cooperative Oncology Group (ECOG) in the
USA[17]. Twenty patients with 2 or 3 IPI risk factors we-
re treated, with no treatment related deaths. Tolerance of
therapy was reported to be good, with a mean of 117 days
to complete all 5 phases of therapy, compared with a me-
dian of 105 days in the Milan study. The reported CR
rate was 80%, although follow-up was too short to analy-
ze survival.
The results of the studies outlined above allow the
following preliminary conclusions to be drawn:
- The use of high dose therapy and ASCT in first
remission (complete or partial) does not improve DFS
or OS for the entire population of patients with advanced
aggressive NHL
- Subset analysis of 2 non-stratified trials has shown
a DFS and OS advantage for the high dose arm, which is
restricted to patients with H/I and H risk disease. No be-
nefit has been observed in these trials for patients with
L/I or L risk disease.
- The use of 'early' intensification, using high dose
therapy and ASCT prior to the completion of full induc-
tion therapy may be inadequate, based on the results of
the LNH-93-3 study
- The Milan HDS protocol is the only regimen to
date which has produced superior EFS compared with
standard dose therapy in poor risk patients in a prospec-
tive randomized trial
- The ECOG study has demonstrated that this che-
motherapy can be safely delivered in a multi-institutional
study.
- Those studies in which sub-set analysis has demon-
strated an advantage to high dose therapy have included
the high dose regimen at the completion of full induc-
tion chemotherapy.
Important studies which may help to clarify the role
of ASCT in this setting are still in progress. The LY02
study of the UKLG/Nordic Lymphoma Study Gro-
up/EBMT and ANZSLG is comparing 6 cycles of CHOP
chemotherapy with 3 cycles of CHOP followed by ASCT
in patients with age-adjusted poor risk disease. The cur-
rent SWOG/ECOG/CALGB study in the United States
has a very similar study design.
The UKCCCR has recently joined the SAKK group
in Switzerland to conduct the 'MISTRAL' study. The de-
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Figure 1. Scheme for high dose sequential therapy
CHOP
HD CTX
PBPC
HD MTX
HD VP16
HD melphalan
HD mitoxantrone
High dose sequential therapy
Table I. Results from randomized comparison of MACOP-B and high
dose sequential therapy - adapted from reference 16
CR FFP  (7yr) EFS  (7yr) FFR  (7yr) OS  (7yr)
HDS 96% 84% 76% 88% 81%
MACOP-B 70% 49% 49% 70% 55%
p 0.001 <0.001 0.004 0.055 0.09
sign of this study is shown in Figure 2. Patients with age-
-adjusted poor risk aggressive NHL will be randomized
between 8 cycles of CHOP chemotherapy, or high dose
sequential therapy. This study is powered to detect a 15%
improvement in 2 year overall survival from 50% to 65%.
It will require 400 randomized patients, and is expected to
take 4 years to complete.
Lymphoblastic lymphoma
S a l v a g e  t h e r a p y
The outlook for adult patients who relapse after induction
therapy for lymphoblastic lymphoma (LBL) is poor. Pa-
tients treated with conventional dose salvage regimens
have a median survival of only 3 to 6 months, with only 5%
to 10% of patients achieving long term survival. Reports of
the use of HDT and ASCT in this setting have been supe-
rior. For example, we have previously reported data from
the EBMT registry for patients undergoing ASCT for re-
lapsed LBL [18]. The responsiveness of disease to 2nd line
conventional chemotherapy was predictive of outcome.
Patients with chemosensitive relapse had long term overall
survival of approximately 30%. Even in the group with
chemoresistant disease at the time of relapse, 14% achie-
ved long term survival. These results suggest that high do-
se therapy and ASCT should be considered as standard for
patients with LBL who relapse after conventional dose
induction, even if the disease is resistant to 2nd line salva-
ge therapy. Although based on registry data only, this is
such a rare entity that randomized trials are very unlikely.
H D T / A S C T  a s  a c o m p o n e n t  o f  f i r s t  l i n e
t h e r a p y  f o r  L B L
The optimal initial therapy for adult LBL remains un-
certain. The use of intensive chemo-/radio-therapy in-
duction regimens, similar to those used for acute lym-
phoblastic leukemia (ALL) produces response rates of
70% to 80%, with 40% to 60% of patients achieving long
term survival. The high complete remission rate, but sub-
sequent high relapse rate has provided the rationale for
attempts to consolidate first remission by the use of HDT
and ASCT.
Several single center and registry based retrospecti-
ve studies have reported high long term survival rates for
patients receiving HDT and ASCT (or allogeneic BMT)
in first remission. In the largest of these, from the EBMT,
we reported a 6 year actuarial overall survival rate of
63% in 265 patients treated in this way [18]. Although
encouraging, these retrospective data must be interpreted
cautiously, and in order to clarify the role of first remis-
sion ASCT in this disease, the UKLG and EBMT have
conducted a randomized trial, the design of which is
shown in Figure 3 [19].
One hundred and nineteen patients were entered
into this study, of whom 98 (82%) responded to induction
therapy. Of these 65 were randomized, 31 to ASCT and
34 to further conventional therapy. Preliminary results
from the trial are shown in Figure 4. There was a trend
for improved relapse free survival in patients receiving
high dose consolidation. This did not achieve statistical si-
gnificance, partly because of the low numbers of patients
on the trial. No difference in overall survival was obse-
rved. In part, this may be because some of those patients
who relapsed after conventional dose consolidation and
maintenance therapy received HDT and ASCT if they
achieved a 2nd CR to salvage therapy.
Although no survival advantage for 1st remission
HDT and ASCT has been shown, the trend for improved
relapse free survival suggests that the high dose approach
should at least be discussed with patients with this disease.
It may reduce the risk of subsequent relapse, and it redu-
ces the overall duration of therapy compared with co-
nventional dose consolidation and maintenance therapy.
Burkitt's and Burkitt-like lymphoma
S a l v a g e  t h e r a p y
As with LBL, the outlook for patients with these disease
who relapse after conventional dose induction therapy is
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Figure 2. Study design of SAKK/UKCCCR Mistral trial
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Figure 3. Study design for UKLG/EBMT lymphoblastic lymphoma trial.
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very poor, only around 10% surviving long term, and me-
dian survivals of only 3 to 6 months. Results from the
EBMT registry show a 3 year actuarial overall survival
of 37% for patients treated with HDT and ASCT for che-
mosensitive relapse, and 7% for those with chemoresi-
stant disease [20]. As with LBL, randomized trials in this
setting are very unlikely, and HDT and ASCT should be
regarded as standard.
H D T / A S C T  a s  a c o m p o n e n t  o f  f i r s t  l i n e
t h e r a p y
Many dose-intensive combination chemotherapy regi-
mens have been used for patients with Burkitt's and Bur-
kitt-like lymphoma, producing response rates of 60% to
85%, and long term relapse free survival rates of 60% to
80%. Single center and registry-based retrospective se-
ries have investigated the role of HDT and ASCT in first
remission. In the largest of these studies, from the EBMT
registry, we reported 3 year actuarial overall and progres-
sion free survival rates of 72% and 73% respectively [20].
Although these results are encouraging, they must be
placed in the context of other approaches in these dise-
ases. Magrath et al have recently reported results of the
NCI 89-C-41 protocol for adult patients with Burkitt's and
Burkitt-like lymphoma [21]. This regimen produced 2
year overall survival rates of over 90%. A multicenter
phase I trial of this regimen has recently been completed
in Europe. Mature results from this study are awaited,
but at present, HDT and ASCT should not be considered
as standard therapy in 1st remission, given the excellent
results of intensive induction regimens.
Aggressive NHL – summary
Data from randomized trials are still needed to clarify
the role of HDT and ASCT in many situations. In those
settings where randomized trials will not be undertaken,
conclusions about the role of ASCT must be based on
retrospective data. Table II summarizes current use of
HDT and ASCT in these diseases.
Table II. Summary of current use of high dose therapy 
and ASCT for aggressive NHL
NHL subtype & status HDT/ASCT indicated?
chemosensitive relapse YES
resistant relapse/induction failure
LBL/Burkitt's/Burkitt-like YES
DLBCL NO
First remission
LBL YES
Burkitt's/Burkitt-like NO
DLBCL (all patients) NO
DLBCL (poor risk) randomized trials only
Hodgkin's disease
S a l v a g e  t h e r a p y  –  f o l l o w i n g  r e l a p s e  a f t e r
c h e m o t h e r a p y
The use of 'conventional dose' salvage therapy in patients
who relapse after treatment with combination chemothe-
rapy produces high remission rates. In a series from the
National Cancer Institute in the USA, in patients re-
lapsing after MOPP (mustine, vincristine, procarbazi-
ne, prednisone), re-treatment with MOPP produced
second complete remission rates of around 50%, with
a median second remission duration of 21 months [22].
The most important prognostic factor for achievement
of second remission was the duration of the initial remis-
sion. In those patients with an initial remission of less
than 12 months, only 29% achieved a second complete re-
mission with MOPP. The second remission rate in those
with an initial remission of greater than 12 months was
93%. Despite this high remission rate in the 'favorable'
group, only 17% were alive and free of disease at 20 years.
Non-cross resistant regimens have also been widely
used as second line therapy for patients with relapsed di-
sease. Encouraging results have been reported in single
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Figure 4. Preliminary results of UKLG/EBMT trial in adult
lymphoblastic lymphoma  A. Relapse free survival, B. Overall survival
A. Hazard ratio = 0.55, p = 0.077
B.  Hazard ratio = 0.94  p = 0.88
center studies using this approach. For example, in studies
from Milan, 5 year progression free survival has been re-
ported in 51% of patients treated with further conventio-
nal chemotherapy following relapse more than 12 months
after treatment with MOPP, ABVD (doxorubicin, ble-
omycin, vinblastine, dacarbazine), or alternating
MOPP/ABVD [23]. Various second line regimens were
used including MOPP, ABVD or CEP (lomustine, eto-
poside, prednimustine).
These results have not been reproduced in multi-
-center studies. In a randomized study conducted by the
Cancer and Leukemia Group B (CALGB), patients rece-
iving ABVD as first line therapy were treated with MOPP
at relapse, with a 5 year failure free survival rate of only
31% [24]. The outcome for patients who received MOPP
as initial therapy, and ABVD at relapse was worse, with
only 15% failure free at 5 years.
Results of the use of HDT and ASCT in this setting
have been superior. Chopra et al have reported a 5 year
freedom from progression rate of 47% in a series of 52
patients receiving HDT and ASCT at first relapse after
combination chemotherapy [25]. Comparable results we-
re reported from Vancouver in 58 patients receiving HDT
and ASCT in first relapse, in whom the 5 year freedom
from progression was 61% [26]. In a study from Stanford
University, the outcome for 60 patients with relapsed or
refractory disease treated with HDT and ASCT was com-
pared with a matched group of historical controls who
received conventional dose salvage therapy [27]. Four
year event free survival (EFS) and freedom from pro-
gression (FFP) were higher in the group treated with
HDT and ASCT although no overall survival difference
was observed. For the group of patients who relapsed
after an initial remission of less than 1 year, an overall su-
rvival advantage was observed for patients receiving high
dose therapy.
In a registry-based study from the European group
for Blood and Marrow Transplantation (EBMT) we re-
ported a 45% event free survival at 5 years in 139 pa-
tients with Hodgkin's disease treated with HDT and
ASCT in first relapse after chemotherapy [28].
The results of two randomized trials comparing high
dose with conventional dose salvage therapy have now
been reported. In a small randomized trial conducted by
the British National lymphoma Investigation (BNLI), 40
patients with Hodgkin's disease in first or subsequent re-
lapse were randomized to receive high dose therapy with
BEAM (carmustine, etoposide, cytosine arabinoside, mel-
phalan) and autologous bone marrow transplantation
(ABMT) or conventional dose therapy, using the same
drugs at lower dose ('mini-BEAM') [29]. There was a si-
gnificant difference in EFS for patients receiving BEAM
compared with mini-BEAM (3 year EFS = 53% for
BEAM versus 10% for mini-BEAM, p = 0.025), although
there was no overall survival difference. The overall survi-
val in this study is, however, difficult to interpret, since so-
me patients who relapsed after mini-BEAM 'crossed over'
to receive BEAM and ASCT and were subsequently pro-
gression free.
The German Hodgkin's Disease Study Group and
EBMT have recently completed a randomized study with
a similar design [30]. One hundred and sixty one patients
with relapsed Hodgkin's disease were entered. All were
initially treated with 2 cycles of Dexa-BEAM (dexame-
thasone, BEAM (carmustine, etoposide, cytosine arabino-
side, melphalan). Responding patients were then treated
according to randomized arm, either with 2 further cour-
ses of Dexa-BEAM, or BEAM and ASCT. One hundred
and thirty nine patients were evaluable. With a median
follow up of 34 months, there was a significant impro-
vement in time to treatment failure (TTF) for patients
receiving BEAM and ASCT compared with those rece-
iving further DexaBEAM. However, there was no diffe-
rence in overall survival. As with the BNLI study, this is
partly due to the ability of HDT and ASCT to salvage
patients who relapsed after receiving conventional dose
therapy.
S a l v a g e  t h e r a p y  –  a f t e r  f a i l u r e  o f  i n d u c -
t i o n  c h e m o t h e r a p y
Patients who do not enter remission after first line combi-
nation chemotherapy have a poor outlook. In a study
from Milan, 41% of patients who failed to respond to al-
ternating MOPP/ABVD and were treated with the CEP
regimen, achieved a complete response, but only 12%
were alive at 5 years, and all of these had active disease
[31]. Similar results were reported from the National
Cancer Institute in the USA [22,] with a 16 month median
overall survival, and from Stanford University, where the
4 year overall survival for patients with primary refracto-
ry Hodgkin's disease was only 38%, with a corresponding
4 year PFS of 19% [27].
Several retrospective studies have reported enco-
uraging results in patients treated with HDT and ASCT
after failure to enter remission. In a series from London,
46 patients with primary refractory Hodgkin's disease we-
re treated with BEAM and ABMT [25]. The 5 year PFS
for this group was 33%. Comparable results have been
observed in Milan using high dose sequential therapy
with ASCT [32]. The group from Stanford reported a 4
year PFS of 52% and OS of 44% in patients with primary
refractory disease receiving HDT and ASCT. These re-
sults were significantly better than those for a matched
population of historical controls who received conven-
tional dose second line therapy [27, 33].
The Autologous Blood and Marrow Transplant Regi-
stry of North America (ABMTR) have recently repor-
ted a series of 122 patients with Hodgkin's disease who
underwent HDT and ASCT having failed to achieve re-
mission after induction chemotherapy [34]. Definition of
induction failure in this series was restricted to patients
who had obvious disease progression after induction the-
rapy, or who had biopsy-proven persistent disease in resi-
dual radiographic abnormalities. The 3 year actuarial
PFS and OS in this series were 38% and 50% respective-
ly. The EBMT have reported comparable results in 175
patients with Hodgkin's disease failing to enter remission
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after one or two induction chemotherapy regimens [35].
This series included patients with disease progression,
and those with either stable, or minimally responsive dise-
ase following initial chemotherapy. The 5 year actuarial
PFS and OS were 36% and 32% respectively.
Although the results of HDT and ASCT appear su-
perior, all of these results must be interpreted cautiously.
In addition to the potential selection bias inherent in re-
trospective analyses, the definition of induction failure
is inconsistent in these studies. Assessment of response in
Hodgkin's disease is problematic, particularly in patients
with bulky mediastinal disease at presentation, where re-
sidual masses are common after chemotherapy [36, 37].
These masses may contain active disease, but may repre-
sent fibrotic masses with no active disease. The group of
patients who have stable, or only minimally responsive
disease after chemotherapy may therefore be distinct
from those who have obvious disease progression.
Only two of the published series have attempted to
address this issue. In the ABMTR series, only patients
with definite disease progression, or those with tissue
confirmation of disease in residual masses were inclu-
ded. In the EBMT series, there was no difference in out-
come for patients who had obvious disease progression
after first line therapy, compared with those who had sta-
ble, or minimally responsive disease.
H D T / A S C T  a s  a c o m p o n e n t  o f  f i r s t  l i n e
t h e r a p y  i n  ' p o o r  r i s k '  H o d g k i n ' s d i s e a s e
In view of the apparent activity of HDT and ASCT for re-
lapsed and refractory Hodgkin's disease, it has also been
used as a component of first line therapy in patients with
'poor risk' disease. In most reports, HDT has been given
to consolidate complete remission in patients thought to
be at high risk of subsequent relapse. These retrospective
studies have observed long-term disease-free survival ra-
tes of 70% to 90% [38-41].
However, interpretation of these data is difficult be-
cause of their retrospective nature and the variable defi-
nition of poor risk disease. A prospective, randomized
trial comparing conventional dose chemotherapy using
ABVD with HDT and ASCT is in progress, but the defi-
nition of 'poor risk' in the eligibility for this trial is contro-
versial [42].
The International Prognostic Factors Project on Ad-
vanced Hodgkin's Disease have recently described repro-
ducible clinical prognostic factors at presentation for pa-
tients with advanced Hodgkin's disease [43], but these
were not available when the present randomized study
was initiated.
However, irrespective of the results of this trial, the
role of HDT and ASCT as a component of first line thera-
py is doubtful. The projected long-term disease free survi-
val for the poorest risk group in the International Pro-
gnostic Factors Project was approximately 40%. Emer-
ging reports of the long-term toxicity of high dose therapy
have identified major effects on reproductive function in
both sexes, as well as a risk of secondary malignancy.
In view of the effectiveness of HDT and ASCT as sa-
lvage therapy, poor risk patients should probably rece-
ive conventional dose, anthracycline-based induction the-
rapy, reserving HDT and ASCT for patients with relapsed
or refractory disease. This approach will mean that 40%
of patients with poor risk disease will not be exposed to
the potential short- and long-term toxicity of HDT, and
the overall survival for the entire cohort of patients is
unlikely to be compromised.
Hodgkin's disease – summary
Current use of HDT and ASCT for patients with
Hodgkin's disease is summarized in Table III. Although
Table III. Summary of current use of high dose therapy and ASCT 
for patients with Hodgkin`s disease
status HDT/ASCT indicated?
2nd or subsequent relapse YES
First relapse after chemotherapy - initial
remission < 1 year YES
First relapse after chemotherapy - initial
remission >1 year YES
Induction failure YES
1st remission in 'poor risk' patients NO (randomized trials only)
there have been few randomized trials, the use of
HDT/ASCT as salvage therapy is now well-established
for patients in 2nd or subsequent relapse after chemothe-
rapy, and for those in first relapse with an initial remission
duration of >1 year. In patients with a shorter initial re-
mission, the poor long term results of conventional dose
salvage justify a high dose approach also. At present, the-
re is no role for HDT and ASCT in the first line treat-
ment of Hodgkin's disease.
John W. Sweetenham M.D. Ph.D.
University of Colorado Health Sciences Center
Division of Medical Oncology-B171
4200 East Ninth Avenue
Denver
Colorado 80262
USA
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